Clinical trials: Population at Risk
Delayed Graft Function
Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)
The purpose of this study was to determine if eculizumab is safe and could be used to prevent delayed graft function (DGF) following kidney transplantation.
- Trial name
- NCT02145182
- Testing
- Eculizumab
- Where
- 78 sites in United States, Australia and 7 more
- Volunteers
- 288 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Fibrillation, Atrial, Atrial Fibrillation
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
This study will allow determination of the pharmacokinetic and pharmacodynamics of SB424323 in a relevant population. The data from this study will be used along with other data to aid in choosing the most appropriate dose for…
- Trial name
- NCT00240643
- Testing
- SB424323
- Where
- 116 sites in United States, Argentina and 23 more
- Volunteers
- 640 people
- Sponsor
- GlaxoSmithKline
Colorectal Cancer Screening, Colorectal Cancer
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
This is a prospective longitudinal study to assess the impact of repeat Cologuard testing at 3 years in average risk patients.
- Trial name
- NCT02419716
- Testing
- Cologuard
- Where
- 40 sites in United States
- Volunteers
- 2,404 people, healthy volunteers welcome
- Sponsor
- Exact Sciences Corporation
ATTR-CM
Implementation of Standardized Early Identification and Diagnosis for Transthyretin Amyloidosis (ATTR) in High-Risk Populations
This multicenter, prospective, single-arm, interventional study will enroll about 4,000 adult patients at high risk of ATTR amyloidosis from around 50 sites in China.
- Trial name
- NCT07338942
- Testing
- implementation of standard early identification and diagnosis of ATTR
- Where
- 48 sites in China
- Volunteers
- 4,000 people
- Sponsor
- AstraZeneca
Delayed Graft Function
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
When a patient receives a kidney transplant particularly if the kidney is from an older donor or one who has had the kidney removed after their heart has stopped, there is a risk that the newly transplanted kidney may not…
- Trial name
- NCT01794663
- Testing
- OPN-305
- Where
- 50 sites in United States, Austria and 9 more
- Volunteers
- 252 people
- Sponsor
- Opsona Therapeutics Ltd.
Insulin Resistance
Effects of Novel Fiber on Glucose Homeostasis in Individuals at Risk for Diabetes
This study will critically evaluate the effects of a novel dietary fiber administered to subjects at high risk for developing diabetes to determine if this intervention will improve insulin sensitivity compared to control product…
- Trial name
- NCT00820807
- Testing
- Novel dietary fiber
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Cargill
Heart Failure, Type 2 Diabetes Mellitus
Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
The primary objective of the study was to compare the effect of sotagliflozin to placebo on total occurrences of cardiovascular (CV) death, hospitalization for heart failure [HHF], and urgent visit for heart failure [HF] in…
- Conditions
- Heart Failure, Type 2 Diabetes Mellitus, Chronic Kidney Diseases
- Trial name
- SCORED (NCT03315143)
- Testing
- Sotagliflozin
- Where
- 754 sites in United States, Argentina and 43 more
- Volunteers
- 10,584 people
- Sponsor
- Lexicon Pharmaceuticals
Moderate Risk of CVD
A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease
The use of acetylsalicylic acid in the primary prevention of cardiovascular events has been extensively studied but to a lesser extent in patients with moderate levels of cardiovascular risk.
- Trial name
- ARRIVE (NCT00501059)
- Testing
- Aspirin (Acetylsalicylic acid, BAYE4465)
- Where
- 466 sites in United States, Germany and 6 more
- Volunteers
- 12,546 people
- Sponsor
- Bayer
Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer
A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups
PanFAM-1 is a clinical study for early detection of pancreatic cancer in high-risk groups. The goals of the study are to assess the performance and diagnostic accuracy of the IMMray™ PanCan-d test compared to standard-of-care…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer, FAMMM - Familial Atypical Mole Malignant Melanoma Syndrome
- Trial name
- NCT03693378
- Where
- 21 sites in United States, Canada and 3 more
- Volunteers
- 1,349 people, healthy volunteers welcome
- Sponsor
- Immunovia, Inc.
Colorectal Cancer
Observational Study of Sub-populations From Cologuard Post-Approval Study (2014-01)
The primary endpoint is to obtain longitudinal information on four sub-populations from the Cologuard Post-Approval Study.
- Trial name
- NCT03705013
- Testing
- Cologuard
- Where
- 20 sites in United States
- Volunteers
- 51 people
- Sponsor
- Exact Sciences Corporation
Cardiovascular Disease
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
The purpose of this phase 3, randomized, placebo controlled, event-driven study is to assess the effect of AZD0780, an oral PCSK9 inhibitor, compared with placebo in reducing the risk of MACE-PLUS in patients with established…
- Trial name
- AZURE-Outcomes (NCT07000357)
- Testing
- AZD0780
- Where
- 1,452 sites in United States, Argentina and 34 more
- Volunteers
- 15,100 people
- Sponsor
- AstraZeneca
Lipid Metabolism Disorders
Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
This study is to demonstrate therapeutic comparability of Fluvastatin sodium Extended Release Tablets 80 mg QD and Fluvastatin sodium Immediate Release Capsules 40 mg BID in LDL-C lowering from baseline to week 12 (endpoint) in…
- Trial name
- NCT01551173
- Testing
- Fluvastatin sodium
- Where
- China
- Volunteers
- 436 people
- Sponsor
- Novartis Pharmaceuticals
Hyperlipidemia
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events
This study is a multicenter, randomized study in subjects with high cholesterol receiving highly effective statins to assess the efficacy, safety and tolerability of Bococizumab (PF-04950615;RN316) to lower LDL-C.
- Trial name
- SPIRE-LDL (NCT01968967)
- Testing
- Bococizumab (PF-04950615; RN316)
- Where
- 249 sites in United States, Canada and 10 more
- Volunteers
- 2,139 people
- Sponsor
- Pfizer
Prediabetes
Effects of Yoghurt Consumption on Glucose Metabolism in Prediabetic Subjects
The purpose of this study is to explore the effects of yoghurt consumption on glucose metabolism in prediabetic subjects.
- Trial name
- SNOWFALL (NCT06836752)
- Testing
- Yoghurt, Milk
- Where
- France
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Danone Global Research & Innovation Center
Gastric Ulcer
Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen
This study uses a randomized, double-blind, controlled design to demonstrate that PN400 (esomeprazole and naproxen) is more effective in reducing the occurrence of gastroduodenal ulcers, dyspepsia, and heartburn in subjects at…
- Trial name
- NCT01129011
- Testing
- PN400 (VIMOVO), Naproxen
- Volunteers
- 420 people
- Sponsor
- POZEN
Breast Cancer, Neutropenia
Safety and Efficacy Study of GCSF Therapy to Treat Patients at High Risk for Chemotherapy Induced Severe Neutropenia
The overall purpose of this study is to assess the dose response, efficacy, and safety of three different dose levels of AVI 014 (granulocyte colony-stimulating factor [G-CSF]) in breast cancer patients at high (>20%) risk for…
- Trial name
- NCT00497809
- Testing
- AVI-014 versus Filgrastim
- Where
- 31 sites in United States, India
- Volunteers
- 189 people
- Sponsor
- AviGenics
Early Detection of Cancer
The PREDICT Study: Prospective Early Detection In a Population at High-risk for Common Malignant Tumor
This is a observational, multicenter study, monitoring the circulating tumor DNA (ctDNA) in people who is at risk of cancers，assessing the sensitivity and specificity of ctDNA detection in early screening of pan-carcinoma.
- Trial name
- NCT04405557
- Where
- 8 sites in China
- Volunteers
- 757 people
- Sponsor
- Geneplus-Beijing Co. Ltd.
Infection
Study to Evalutate Long-term Immunity of Hantavax in High Risk Population of HFRS
This study was aimed evaluate long-term immunity response by neutralizing antibody test of adults in high risk population of HFRS .
- Trial name
- NCT02360514
- Testing
- Hantavax injection
- Volunteers
- 226 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Hyperlipidemia
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events
This study is a multicenter, double-blind, randomized study to access the efficacy, safety and tolerability of Bococizumab (PF-04950615; RN316) in subjects with hyperlipidemia receiving background statin therapy.
- Trial name
- SPIRE-LL (NCT02100514)
- Testing
- Bococizumab (PF-04950615; RN316)
- Where
- 223 sites in United States, Canada and 10 more
- Volunteers
- 746 people
- Sponsor
- Pfizer
Mucopolysaccharidosis (MPS)
Mucopolysaccharidosis (MPS) I, II, and VI Screening in a High-Risk Population With Previous Surgical Repair or Presence of Inguinal and/or Umbilical Hernia in Combination With Pediatric ENT Surgery (The HATT Project)
Mucopolysaccharidosis (MPS) type II (MPS II; Hunter syndrome) is a rare, X-linked disease caused by a deficiency of the lysosomal enzyme iduronate-2-sulfatase (I2S) and occurs almost exclusively in boys, with an incidence of…
- Trial name
- NCT02095015
- Where
- 14 sites in United States, Canada and 5 more
- Volunteers
- 159 people
- Sponsor
- Shire